COVID-19 and hydroxychloroquine: Is the wonder drug failing?
作者信息
Paliani Ugo, Cardona Andrea
机构信息
Division of Internal Medicine and Sport Cardiology. Media Valle del Tevere Hospital, Todi, Umbria, Italy; Umbria Covid Hospital, Todi, Umbria, Italy.
Division of Internal Medicine and Sport Cardiology. Media Valle del Tevere Hospital, Todi, Umbria, Italy; Umbria Covid Hospital, Todi, Umbria, Italy; Division of Cardiovascular Medicine - Department of Internal Medicine. The Ohio State University, Columbus, Ohio, USA.
出版信息
Eur J Intern Med. 2020 Aug;78:1-3. doi: 10.1016/j.ejim.2020.06.002. Epub 2020 Jun 4.
Abstract
摘要
相似文献
1
COVID-19 and hydroxychloroquine: Is the wonder drug failing?新冠病毒与羟氯喹：神药失效了吗？
Eur J Intern Med. 2020 Aug;78:1-3. doi: 10.1016/j.ejim.2020.06.002. Epub 2020 Jun 4.
2
[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?].在此次新冠疫情期间短期使用羟氯喹治疗的情况下，是否需要进行眼科监测？
J Fr Ophtalmol. 2020 Jun;43(6):548-549. doi: 10.1016/j.jfo.2020.04.014. Epub 2020 Apr 30.
3
Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.风湿科医生对羟氯喹治疗 COVID-19 的看法。
Emerg Microbes Infect. 2020 Dec;9(1):830-832. doi: 10.1080/22221751.2020.1760145.
4
QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.在新冠肺炎患者使用羟氯喹和/或阿奇霉素期间控制QT间期以预防尖端扭转型室速
Arq Bras Cardiol. 2020 Jun;114(6):1061-1066. doi: 10.36660/abc.20200389. Epub 2020 Jul 3.
5
Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.探索性 COVID-19 治疗中药物相互作用对 QTc 间期的影响因素。
Heart Rhythm. 2020 Jul;17(7):e231-e232. doi: 10.1016/j.hrthm.2020.04.016. Epub 2020 Apr 14.
6
Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era.药物性嗜酸性粒细胞增多和全身症状综合征与羟氯喹有关，羟氯喹这种老药在新冠疫情时代备受关注。
Dermatol Ther. 2020 Jul;33(4):e13499. doi: 10.1111/dth.13499. Epub 2020 May 22.
7
[Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine].[新型冠状病毒大流行期间获得性长QT综合征的风险。聚焦于羟氯喹]
Orv Hetil. 2020 Apr 1;161(17):689-691. doi: 10.1556/650.2020.31817.
8
BET 2: Hydroxychloroquine in the treatment of COVID-19.BET 2：羟氯喹治疗2019冠状病毒病
Emerg Med J. 2020 Jul;37(7):451-453. doi: 10.1136/emermed-2020-210221.3.
9
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.氯喹和羟氯喹用于治疗新型冠状病毒肺炎的安全性考量
Clin Microbiol Infect. 2020 Sep;26(9):1276-1277. doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.
10
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.新冠病毒感染患者使用氯喹/羟氯喹治疗时的QTc评估：致编辑的一封信
Eur J Clin Invest. 2020 Nov;50(11):e13407. doi: 10.1111/eci.13407. Epub 2020 Sep 25.
引用本文的文献
1
Factors Associated with 28-day Critical Illness Development During the First Wave of COVID-19.新冠疫情第一波期间与28天危重症发展相关的因素
Infect Dis Clin Microbiol. 2023 Jun 23;5(2):94-105. doi: 10.36519/idcm.2023.206. eCollection 2023 Jun.
2
Computational studies reveal Fluorine based quinolines to be potent inhibitors for proteins involved in SARS-CoV-2 assembly.计算研究表明，含氟喹啉是参与新型冠状病毒组装的蛋白质的有效抑制剂。
J Fluor Chem. 2021 Oct;250:109865. doi: 10.1016/j.jfluchem.2021.109865. Epub 2021 Aug 11.
3
Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication.靶向新型赖氨酸特异性去甲基化酶1（LSD1）依赖性血管紧张素转换酶2（ACE2）去甲基化结构域可抑制新型冠状病毒2（SARS-CoV-2）复制。
Cell Discov. 2021 May 24;7(1):37. doi: 10.1038/s41421-021-00279-w.
4
Embracing the Uncertainty: an Important Lesson from COVID-19.拥抱不确定性：来自新冠疫情的重要一课。
J Gen Intern Med. 2021 Nov;36(11):3562-3564. doi: 10.1007/s11606-021-06809-2. Epub 2021 Apr 26.
5
Familiar Dermatologic Drugs as Therapies for COVID-19.常见皮肤科药物在 COVID-19 治疗中的应用。
Actas Dermosifiliogr (Engl Ed). 2021 Feb;112(2):118-126. doi: 10.1016/j.ad.2020.09.004. Epub 2020 Oct 10.
6
COVID-19 associated complications and potential therapeutic targets.COVID-19 相关并发症及潜在治疗靶点。
Eur J Pharmacol. 2020 Nov 5;886:173548. doi: 10.1016/j.ejphar.2020.173548. Epub 2020 Sep 12.
7
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.羟氯喹、甲氨蝶呤和秋水仙碱的益处和不良反应：寻找可再利用的药物候选物。
Rheumatol Int. 2020 Nov;40(11):1741-1751. doi: 10.1007/s00296-020-04694-2. Epub 2020 Sep 2.
8
COVID-19 and hydroxychloroquine: Let the available data speak for themselves.新型冠状病毒肺炎与羟氯喹：让现有数据来说话。
Eur J Intern Med. 2020 Oct;80:121. doi: 10.1016/j.ejim.2020.07.017. Epub 2020 Jul 21.
9
Sex-related differences in COVID-19 lethality.新冠病毒致死率的性别差异。
Br J Pharmacol. 2020 Oct;177(19):4375-4385. doi: 10.1111/bph.15207. Epub 2020 Aug 5.
10
Chloroquine and COVID-19: A western medical and scientific drift?氯喹与2019冠状病毒病：西方医学与科学的偏离？
Eur J Intern Med. 2020 Aug;78:4-5. doi: 10.1016/j.ejim.2020.06.020. Epub 2020 Jun 23.
本文引用的文献
1
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).COVID-19 住院患者使用羟氯喹（无论是否联合使用阿奇霉素）导致 QT 间期延长的风险。
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
2
Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤稿——羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎：一项多国注册研究分析
Lancet. 2020 Jun 13;395(10240):1820. doi: 10.1016/S0140-6736(20)31324-6. Epub 2020 Jun 5.
3
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.羟氯喹治疗需要吸氧的 COVID-19 肺炎患者的临床疗效：利用常规护理数据进行的观察性对比研究。
BMJ. 2020 May 14;369:m1844. doi: 10.1136/bmj.m1844.
4
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.纽约州 COVID-19 患者住院死亡率与羟氯喹或阿奇霉素治疗的关联。
JAMA. 2020 Jun 23;323(24):2493-2502. doi: 10.1001/jama.2020.8630.
5
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的观察性研究。
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
6
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).急件：针对新型冠状病毒病（COVID-19）可能的药物治疗的 QTc 延长和致扭转型心动过速的潜在风险的应对和规避指导建议。
Mayo Clin Proc. 2020 Jun;95(6):1213-1221. doi: 10.1016/j.mayocp.2020.03.024. Epub 2020 Apr 7.
7
Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.2019年冠状病毒病大流行期间羟氯喹短缺对系统性红斑狼疮患者的潜在后果
J Rheumatol. 2020 Jun 1;47(6):787-790. doi: 10.3899/jrheum.200395. Epub 2020 Apr 8.
8
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.结构和分子建模研究揭示了氯喹和羟氯喹抗 SARS-CoV-2 感染的新作用机制。
Int J Antimicrob Agents. 2020 May;55(5):105960. doi: 10.1016/j.ijantimicag.2020.105960. Epub 2020 Apr 3.
9
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
10
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.心血管考虑因素在 COVID-19 大流行期间的患者、医护人员和卫生系统。
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371. doi: 10.1016/j.jacc.2020.03.031. Epub 2020 Mar 19.
Zotero 插件